Skip to main content
Log in

Blinatumomab: First Global Approval

  • R&D Insight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Blinatumomab (BLINCYTO™) is a novel, bispecific T-cell engaging antibody that binds cluster of differentiation (CD) 19 antigens on blast cells while also binding and activating the CD3/T cell receptor complex, causing cell lysis. The antibody is being developed by Amgen as a treatment for haematological cancers that originate from B cell lines. Blinatumomab was approved by the US FDA in December 2014 for the treatment of adults with Philadelphia chromosome (Ph)-negative relapsed/refractory B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). It is awaiting approval for this indication in the EU and is in phase III development in various countries. This article summarizes the milestones in the development of blinatumomab leading to its first approval for the treatment of Ph-negative BCP-ALL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Portell CA, Wenzell CM, Advani AS. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol. 2013;5(Suppl 1):5–11.

    PubMed Central  CAS  PubMed  Google Scholar 

  2. Litzow MR. Pharmacotherapeutic advances in the treatment of acute lymphoblastic leukaemia in adults. Drugs. 2011;71:415–42.

    CAS  PubMed  Google Scholar 

  3. Micromet Inc. Micromet receives European Orphan Drug Designation for treatment of acute lymphoblastic leukemia with BiTE antibody blinatumomab [media release]. 3 Aug 2009. http://www.micromet.de.

  4. Amgen Inc. FDA approves BLINCYTO™ (blinatumomab) immunotherapy for the treatment of relased or refractory B-cell precursor acute lymphoblastic leukemia [media release]. 3 Dec 2014. http://www.amgen.com.

  5. Amgen Inc. Blincyto™ (blinatumomab) for injection, for intravenous use: US prescribing information. 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/12555lbl.pdf. Accessed 23 Dec 2014.

  6. Amgen Inc. Amgen’s BiTE® immunotherapy blinatumomab receives FDA priority review designation in acute lymphoblastic leukemia [media release]. 9 Oct 2014. http://www.amgen.com.

  7. AstraZeneca Inc. AstraZeneca successfully completes acquisition of MedImmune [media release]. 19 June 2007. http://www.astrazeneca.com.

  8. Micromet Inc. Micromet buys out MedImmune’s remaining rights to blinatumomab [media release]. 5 Nov 2009. http://www.micromet.de.

  9. Micromet Inc. Micromet, Inc. to regain rights to blinatumomab in North America; reports financial results for the fourth quarter and full year ended December 31, 2008 [media release]. 12 Mar 2009. http://www.micromet-inc.com.

  10. MedImmune Inc. MedImmune and Micromet sign agreement to co-develop treatment for B cell tumors [media release]. 9 June 2003. http://www.medimmune.com.

  11. Micromet A. G. Micromet and CancerVax complete merger to form Micromet, Inc [media release]. 5 May 2006. http://www.micromet-inc.com.

  12. Amgen Inc. Amgen completes tender offer for outstanding shares of Micromet, Inc [media release]. 7 Mar 2012. http://www.amgen.com.

  13. AdisInsight databases. Blinatumomab: at a glance. 2014. http://www.springer.com/gp/adis/products-services/adisinsight-databases. Accessed 6 Jan 2015.

  14. Amgen Inc. Amgen and Astellas announce Japan alliance [media release]. 29 May 2013. http://www.amgen.com.

  15. Micromet Inc. Micromet signs CRADA with National Cancer Institute to expand development of blinatumomab [media release]. 9 Jan 2012. http://www.micromet.de.

  16. Lonza. Micromet enters into agreement with Lonza for the manufacture of blinatumomab [media release]. 24 Nov 2009. http://www.lonza.com.

  17. Bargou RC. Preclinical and clinical development of blinatumomab in NHL and ALL [abstract no. V888]. Oncol Res Treat. 2014;37(Supplement(5)):297.

    Google Scholar 

  18. Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012;119(26):6226–33.

    Article  CAS  PubMed  Google Scholar 

  19. Gore L, Zugmaier G, Handgretinger R, et al. Cytological and molecular remissions with blinatumomab treatment in second or later bone marrow relapse in pediatric acute lymphoblastic leukemia (ALL) [abstract no. 10007]. J Clin Oncol. 2013;31(15 Suppl 1).

  20. d’Argouges S, Wissing S, Brandl C, et al. Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leuk Res. 2009;33(3):465–73.

    Article  PubMed  Google Scholar 

  21. Wong R, Pepper C, Brennan P, et al. Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells. Haematologica. 2013;98(12):1930–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Feulner J, Aigner M, Kischel R, et al. A novel CD33/CD3-bispecific BiTE antibody can effectively recruit autologous T cells from AML-patients for in vitro cell lysis of CD33+ blasts [abstract]. Cancer Res. 2012;72(8 Suppl 1).

  23. Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493–8.

    Article  CAS  PubMed  Google Scholar 

  24. Topp MS, Gökbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120(26):5185–7.

    Article  CAS  PubMed  Google Scholar 

  25. Zugmaier G, Topp MS, Alekar S, et al. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J. 2014;4:244.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Topp MS, Gökbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014. doi:10.1200/JCO.2014.56.3247.

    PubMed  Google Scholar 

  27. Goekbuget N, Dombret H, Bonifacio M, et al. BLAST: a confirmatory, single-arm, phase 2 study of blinatumomab, a bispecific T-cell engager (BiTE®) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL) [abstract no. 379]. In: 56th Annual Meeting of the American Society of Hematology; 6–9 December 2014; San Francisco.

  28. Göbeler ME, Viardot A, Noppeney R, et al. Blinatumomab (CD3/CD19 Bite®) antibody) results in a high response rate in patients with relapsed non-hodgkin lymphoma (NHL) including mantle cell lymphoma (MCL) and diffuse large B cell lymphoma (DLBCL) [abstract no. V646]. Onkologie. 2011;34(suppl(6)):190–1.

    Google Scholar 

  29. Goebeler ME, Viardot A, Kufer P, et al. Final results from a phase 1 study of blinatumomab in patients with relapsed/refractory non-hodgkin’s lymphoma [abstract]. Hematol Oncol. 2013;31:197.

    Article  Google Scholar 

  30. Viardot A, Goebeler M, Pfreundschuh M, et al. Open-label phase 2 study of bispecific T-cell engager (BiTE®) antibody blinatumomab in patients (pts) with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) [abstract no. V123]. Oncol Res Treat. 2014;37(Supplement(5)):33.

    Google Scholar 

  31. Locatelli F, Gore L, Zugmaier G, et al. Blinatumomab in pediatric patients with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukaemia (BCP-ALL): a phase I/II study [abstract]. Bone Marrow Transpl. 2014;49:S361–2.

    Article  Google Scholar 

  32. Whitlock J, Von Stackelberg A, Handgretinger R, et al. Blinatumomab in pediatric patients with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (BCP-ALL): a phase 1/2 study [abstract]. Pediatr Blood Cancer. 2014;61:S138.

    Google Scholar 

  33. Schlegel P, Lang P, Zugmaier G, et al. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica. 2014;99(7):1212–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Disclosure

The preparation of this report was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. M. Sanford is a salaried employee of Adis, Springer SBM.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mark Sanford.

Additional information

This profile has been extracted and modified from the Adis R&D Insight drug pipeline database. Adis R&D Insight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sanford, M. Blinatumomab: First Global Approval. Drugs 75, 321–327 (2015). https://doi.org/10.1007/s40265-015-0356-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-015-0356-3

Keywords

Navigation